Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer-Reference-Cited by-同舟云学术

Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer

Published:2021-07-10 Issue:9 Volume:112 Page:3616-3626
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Shiota Masaki¹^ORCID,Terada Naoki²,Kitamura Hiroshi³,Kojima Takahiro⁴,Saito Toshihiro⁵,Yokomizo Akira⁶,Kohei Naoki⁷,Goto Takayuki⁸,Kawamura Sadafumi⁹,Hashimoto Yasuhiro¹⁰,Takahashi Atsushi¹¹,Kimura Takahiro¹²,Tabata Ken‐ichi¹³,Tomida Ryotaro¹⁴,Hashimoto Kohei¹⁵,Sakurai Toshihiko¹⁶,Shimazui Toru¹⁷,Sakamoto Shinichi¹⁸^ORCID,Kamiyama Manabu¹⁹,Tanaka Nobumichi²⁰,Mitsuzuka Koji²¹,Kato Takuma²²,Narita Shintaro²³^ORCID,Yasumoto Hiroaki²⁴,Teraoka Shogo²⁵,Kato Masashi²⁶,Osawa Takahiro²⁷^ORCID,Nagumo Yoshiyuki⁴,Matsumoto Hiroaki²⁸^ORCID,Enokida Hideki²⁹^ORCID,Sugiyama Takayuki³⁰,Kuroiwa Kentaro³¹,Inoue Takahiro³²,Sugimoto Mikio²²,Mizowaki Takashi³³,Kamoto Toshiyuki²,Nishiyama Hiroyuki⁴,Eto Masatoshi¹,

Affiliation:

1. Department of Urology Kyushu University Fukuoka Japan

2. Department of Urology Miyazaki University Miyazaki Japan

3. Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research University of Toyama Toyama Japan

4. Department of Urology University of Tsukuba Hospital Tsukuba Japan

5. Department of Urology Niigata Cancer Center Hospital Niigata Japan

6. Department of Urology Harasanshin Hospital Fukuoka Japan

7. Department of Urology Shizuoka General Hospital Shizuoka Japan

8. Department of Urology Kyoto University Kyoto Japan

9. Department of Urology Miyagi Cancer Center Natori Japan

10. Department of Urology Hirosaki University Hirosaki Japan

11. Department of Urology Hakodate Goryokaku Hospital Hakodate Japan

12. Department of Urology Jikei University Tokyo Japan

13. Department of Urology Kitasato University Sagamihara Japan

14. Department of Urology Shikoku Cancer Center Matsuyama Japan

15. Department of Urology Sapporo Medical University Sapporo Japan

16. Department of Urology Yamagata University Yamagata Japan

17. Department of Urology Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center Kasama Japan

18. Department of Urology Chiba University Chiba Japan

19. Department of Urology University of Yamanashi Hospital Chuo Japan

20. Department of Urology Nara Medical University Kashihara Japan

21. Department of Urology Tohoku University Sendai Japan

22. Department of Urology Kagawa University Kagawa Japan

23. Department of Urology Akita University Akita Japan

24. Department of Urology Shimane University Izumo Japan

25. Department of Urology Tottori University Yonago Japan

26. Department of Urology Nagoya University Nagoya Japan

27. Department of Renal and Genitourinary Surgery Hokkaido University Sapporo Japan

28. Department of Urology Yamaguchi University Ube Japan

29. Department of Urology Kagoshima University Kagoshima Japan

30. Department of Urology Hamamatsu University School of Medicine Hamamatsu Japan

31. Department of Urology Miyazaki Prefectural Miyazaki Hospital Miyazaki Japan

32. Department of Nephro‐Urologic Surgery and Andrology Mie University Graduate School of Medicine Tsu Japan

33. Department of Radiation Oncology & Image‐applied Therapy Kyoto University Kyoto Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15038

Reference27 articles.

1. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer

2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

3. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

4. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

5. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive model of castration resistance in advanced prostate cancer by machine learning using genetic and clinical data: KYUCOG-1401-A study;BJC Reports;2024-09-09

2. The Omission of Upfront Treatment Intensification Does Not Adversely Affect Oncological Outcomes in a Subset of Castration-Highly Sensitive Metastatic Prostate Cancer;In Vivo;2024

3. Pretreatment Lymphocyte to C-Reactive Protein Ratio: An Independent Predictor of Overall Survival in Metastatic Hormone-Naïve Prostate Cancer Patients;Clinical Genitourinary Cancer;2023-12

4. Longitudinal change in castration-resistant prostate cancer biomarker AST/ALT ratio reflects tumor progression;Scientific Reports;2023-09-15

5. TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis;Clinical Genitourinary Cancer;2023-09